Serum PAI-1 levels in type 2 diabetic patients on sitagliptin treatment.

Trial Profile

Serum PAI-1 levels in type 2 diabetic patients on sitagliptin treatment.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jun 2012

At a glance

  • Drugs Sitagliptin (Primary) ; Antihyperglycaemics
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 03 Jun 2012 Actual end date (Mar 2012) added as reported by University Hospital Medical Information Network - Japan.
    • 03 Jun 2012 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan.
    • 03 Jun 2011 Planned end date (1 Oct 2010) added according to University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top